JP2004531560A5 - - Google Patents

Download PDF

Info

Publication number
JP2004531560A5
JP2004531560A5 JP2002591001A JP2002591001A JP2004531560A5 JP 2004531560 A5 JP2004531560 A5 JP 2004531560A5 JP 2002591001 A JP2002591001 A JP 2002591001A JP 2002591001 A JP2002591001 A JP 2002591001A JP 2004531560 A5 JP2004531560 A5 JP 2004531560A5
Authority
JP
Japan
Prior art keywords
composition
pentahydroxy
epoxy
effective amount
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002591001A
Other languages
English (en)
Other versions
JP2004531560A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/015784 external-priority patent/WO2002094284A1/en
Publication of JP2004531560A publication Critical patent/JP2004531560A/ja
Publication of JP2004531560A5 publication Critical patent/JP2004531560A5/ja
Pending legal-status Critical Current

Links

Claims (10)

  1. ドライアイおよび眼の湿潤を必要とする他の障害の処置のための薬学的組成物であって、薬学的受容可能なキャリアおよび薬学的有効量の22,29−エポキシ−3,4,6,7,29−ペンタヒドロキシ−(3α,4β,5α,6α,7β,14β,22S)−スチグマスタン−15−オンを含む組成
  2. 請求項1に記載の薬学的組成物であって、前記22,29−エポキシ−3,4,6,7,29−ペンタヒドロキシ−(3α,4β,5α,6α,7β,14β,22S)−スチグマスタン−15−オンの薬学的有効量が、0.001〜5.0%(w/v)である、組成物
  3. 請求項2に記載の薬学的組成物であって、前記22,29−エポキシ−3,4,6,7,29−ペンタヒドロキシ−(3α,4β,5α,6α,7β,14β,22S)−スチグマスタン−15−オンの薬学的有効量が、0.001〜1.0%(w/v)である、組成物
  4. 請求項1に記載の薬学的組成物であって、前記組成物が、前記眼への所投のために処方される、組成物
  5. 請求項1に記載の薬学的組成物であって、前記ドライアイおよび眼の湿潤を必要とする他の障害が、屈折手術に関連するドライアイの症状である、組成物
  6. ドライアイおよび眼の湿潤を必要とする他の障害の処置用の医薬の製造のための使用であって、薬学的組成物が、薬学的受容可能なキャリアおよび薬学的有効量の22,29−エポキシ−3,4,6,7,29−ペンタヒドロキシ−(3α,4β,5α,6α,7β,14β,22S)−スチグマスタン−15−オンを含む、使用。
  7. 請求項6に記載の使用であって、前記22,29−エポキシ−3,4,6,7,29−ペンタヒドロキシ−(3α,4β,5α,6α,7β,14β,22S)−スチグマスタン−15−オンの薬学的有効量が、0.001〜5.0%(w/v)である、使用。
  8. 請求項6に記載の使用であって、前記22,29−エポキシ−3,4,6,7,29−ペンタヒドロキシ−(3α,4β,5α,6α,7β,14β,22S)−スチグマスタン−15−オンの薬学的有効量が、0.001〜1.0%(w/v)である、使用。
  9. 請求項6に記載の使用であって、前記組成物が、前記眼への局所投与のために処方される、使用。
  10. 請求項6に記載の使用であって、前記ドライアイおよび眼の湿潤を必要とする他の障害が、屈折手術に関連するドライアイの症状である、使用。
JP2002591001A 2001-05-21 2002-05-17 ドライアイ障害を処置する方法 Pending JP2004531560A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29250001P 2001-05-21 2001-05-21
PCT/US2002/015784 WO2002094284A1 (en) 2001-05-21 2002-05-17 Method of treating dry eye disorders

Publications (2)

Publication Number Publication Date
JP2004531560A JP2004531560A (ja) 2004-10-14
JP2004531560A5 true JP2004531560A5 (ja) 2006-01-05

Family

ID=23124938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002591001A Pending JP2004531560A (ja) 2001-05-21 2002-05-17 ドライアイ障害を処置する方法

Country Status (10)

Country Link
US (1) US20030008853A1 (ja)
EP (1) EP1392322A1 (ja)
JP (1) JP2004531560A (ja)
CN (1) CN1239161C (ja)
BR (1) BR0209882A (ja)
CA (1) CA2447918A1 (ja)
MX (1) MXPA03010633A (ja)
PL (1) PL367097A1 (ja)
WO (1) WO2002094284A1 (ja)
ZA (1) ZA200308770B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005016392D1 (de) 2004-03-25 2009-10-15 Bausch & Lomb Verwendung von loteprednoletabonat zur behanldung von trockenen augen
AU2007253776B2 (en) * 2006-05-19 2012-04-26 Arrowhead Research Corporation RNAi-mediated inhibition of tumor necrosis factor alpha-related conditions
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US527851A (en) * 1894-10-23 Process of reducing aluminium
US3991759A (en) * 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4131651A (en) * 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) * 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4883658A (en) * 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4744980A (en) * 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) * 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) * 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5075104A (en) * 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ZA912797B (en) * 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
ES2084722T3 (es) * 1990-05-29 1996-05-16 Boston Ocular Res Composicion para tratamiento del ojo seco.
DK0495421T3 (da) * 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
JPH07508716A (ja) * 1992-04-21 1995-09-28 ザ スキーペンズ アイ リサーチ インスティテュート,インコーポレイテッド シェーグレン症候群における眼のアンドロゲン療法
US5506221A (en) * 1992-12-24 1996-04-09 University Of British Columbia Contignasterol, and related 3-alpha hydroxy-6-alpha hydroxy-7-beta hydroxy-15-keto-14-beta steroids useful as anti-inflammatory and anti-thrombosis agents
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US5800807A (en) * 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
WO1998053806A1 (fr) * 1997-05-26 1998-12-03 New Vision Co., Ltd. Compositions medicinales a administration topique renfermant les vitamines d et les vitamines k
US6096733A (en) * 1998-12-10 2000-08-01 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
WO2002086076A2 (en) * 2001-04-19 2002-10-31 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the nf-kb pathway
US20040076691A1 (en) * 2002-01-16 2004-04-22 David Haines Anti-inflammatory formulations

Similar Documents

Publication Publication Date Title
US9919050B2 (en) Compositions comprising azelastine
JPS6034925B2 (ja) 持続性鼻腔用製剤およびその製造法
WO2006017505A3 (en) Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
TW201016209A (en) Intranasal compositions, dosage forms and methods of treatments
AU2002361918A1 (en) Aerosolized decongestants for the treatment of sinusitis
EP1420760A2 (en) Aerosolized decongestants for the treatment of sinusitis
JP2006503913A5 (ja)
JP2009501797A5 (ja)
AU2003301747A8 (en) Pharmaceutical compositions suitable for the treatment of ophthalmic diseases
ES2266288T3 (es) Pulverizador nasal tixotropico.
JP2005508963A5 (ja)
JP2004531560A5 (ja)
JP2002540148A5 (ja)
JP2007504268A5 (ja)
NO20020342D0 (no) Formuleringer av steroidlösninger for inhalasjonsadministrasjon
KR100910848B1 (ko) 알러지성 비염 치료약물을 유효성분으로 함유하는 비강분무용 마이크로스피어 및 이의 제조방법
JPH0977656A (ja) 点眼用エアゾル組成物
AU2012201428B2 (en) Compositions comprising azelastine and methods of use thereof
JP2002523362A5 (ja)
WO2007046113A3 (en) Novel pharmaceutical composition comprising alkaloid and process thereof
CN101138586A (zh) 核黄青黛口腔溃疡贴片
JP2006503049A5 (ja)
Lambert A review of the active ingredients and excipients in cough medicine: ear, nose and throat
Lorber et al. Desloratadine is effective at relieving nasal congestion, as demonstrated in three placebo-controlled trials in patients with seasonal allergic rhinitis
Chaplin et al. Nasal steroids: concise guide to properties and recommended use